Zynerba Pharmaceuticals (ZYNE)

[surfgreen]

In all fairness sometimes quitting and re-focusing is the best strategy. This is especially true in the US where pursuing development of a failed drug is super expensive and can bankrupt a start up biopharma. Focusing on orphan and near-orphan drug is a smart move and they have 66M in the bank to fund them for 2 years. I'l continue to hold as long as continued drug trials show promise.